New data show treatment with Lilly’s neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent – Lilly Commentary: Lilly antibody combo therapy cuts risk of COVID-19 deaths – Reuters   Commentary on Twitter 1st Phase 3 trial results on #SARSCoV2 monoclonal antibody combination with very positive […]

The post [Press release – not published yet] Neutralizing antibodies bamlanivimab and etesevimab together reduced risk of COVID-19 hospitalizations and death by 70 percent appeared first on Links Medicus.